JUNS: Jupiter Neurosciences P/E Multiple
Jupiter Neurosciences Inc (JUNS) possesses robust patent protection for its brain-delivery technologies and significant influence within the US scientific community, despite strict FDA oversight. The brand has earned recognition for developing breakthrough neuroprotective agents. This price chart illustrates a P/E ratio of -0.30. The company's prospects rely on the transition to full-scale clinical trials and the pursuit of new grants.
Comprehensive metric breakdowns and analytics for Jupiter Neurosciences Inc (JUNS)
- share price and consensus valuation forecast:
- market capitalization information:
- company book value details:
- company liabilities and liquidity data:
Aggregate Debt to Capital Jupiter Neurosciences Inc|JUNS - Long-Term Debt to Capital|Current Liabilities to Capital jupiterneurosciences.com|JUNS - Company Debts|Debt to Net Assets Ratio Jupiter Neurosciences Inc|JUNS - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Jupiter Neurosciences|Immediate Liquidity Ratio jupiterneurosciences.com
- net income and valuation multiples indicators:
JUNS - Net Profit|Expected Net Profit Jupiter Neurosciences Inc|JUNS - Price to Earnings Ratio|Forward P/E Multiple Jupiter Neurosciences, Inc.|JUNS - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Jupiter Neurosciences Inc|JUNS - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Jupiter Neurosciences|JUNS - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months jupiterneurosciences.com|JUNS - Earnings growth in current year|Expected earnings per share growth for next year Jupiter Neurosciences Inc
Comprehensive company analysis:Jupiter Neurosciences, Inc. - JUNS
Investors are assessing the stability of Jupiter Neurosciences Inc (JUNS) via the P/E ratio, which relates market capitalization to net income to determine the investment payback period. By analyzing the relative P/E valuation of Jupiter Neurosciences Inc (JUNS), one can understand the extent to which the market prices in the efficiency of a lean team of neurobiologists, whose loyalty and scientific potential in Alzheimer's disease therapy drive the fundamental value of the business.
Competing companies
BIIB (biogen.com) - Market Price to Net Income Ratio|Price to Earnings Ratio NBIX (Neurocrine Biosciences, Inc.)|P/E Multiple Regencell Bioscience Ltd (RGC)|Price to Earnings Ratio Axsome Therapeutics Inc AXSM|ACAD (ACADIA Corp) - Market Cap to Net Income|Xenon Pharmaceuticals - P/E Multiple|Business Payback Period vikingtherapeutics.com VKTX|SUPN (Supernus) - Price to Earnings Ratio|CPRX: Market Price to Net Income Ratio|DNLI (Denali Therapeutics Inc) - P/E Multiple|Market Cap to Earnings Harmony Corp HRMY|Price to Earnings Ratio Biohaven Ltd. (BHVN)|AMLX (amylyx.com) - Company Value to Net Income|Trevi Therapeutics, Inc. - Price to Earnings Ratio|Company Value to Net Income PRAX|AVXL - Price to Earnings Ratio|CBLL (CeriBell EEG) - Price to Earnings Multiple|PRTA: P/E Multiple|Market Cap to Earnings Alector (ALEC)|Price to Earnings Ratio ANNX|P/E Multiple Omeros Corp.|Price to Earnings Ratio Neurogene Corp (NGNE)|ACIU (AC Immune Inc) - Company Value to Net Income|Price to Earnings Ratio Voyager Therapeutics VYGR|neumoratx.com (NMRA) - Market Cap to Earnings|SCLX - Price to Earnings Ratio|Business Payback Period Tevogen Bio Holdings Inc. TVGN|ACOG: P/E Multiple|Price to Earnings Ratio Cognition Therapeutics Inc.|IKT (Inhibikase Therapeutics) - P/E Multiple|cassavasciences.com (SAVA) - Business Payback Period|P/E Multiple ASRT|COYA - Market Cap to Earnings|Price to Earnings Ratio Vistagen VTGN|OVID: Price to Earnings Multiple|Acumen Pharmaceuticals - P/E Multiple|cervomed.com (CRVO) - Price to Earnings Ratio|ATHE: P/E Multiple|Market Cap to Earnings Clene (CLNN)|Price to Earnings Ratio PepGen Inc|Relmada Corp (RLMD) - Business Payback Period|Price to Earnings Ratio ANVS (Annovis Bio, Inc.)|GRCE (gracetx.com) - Company Value to Net Income|P/E Multiple AIFF (Firefly Neuroscience)|Business Payback Period ANEW Medical (KLTO)|NRSN - Price to Earnings Ratio|RVPH (Reviva Pharmaceuticals, Inc.) - Price to Earnings Multiple|MTVA: P/E Multiple|Price to Earnings Ratio neuraxis.com|Price to Earnings Ratio Helius Medical Technologies, Inc.|PASG (Passage Bio Corp) - Market Price to Net Income Ratio|Price to Earnings Ratio NEUP (Neuphoria Therapeutics Inc.)|P/E Multiple Minerva (NERV)|Price to Earnings Ratio Athira Pharma, Inc. ATHA|ADXN: Price to Earnings Multiple|ALZN - Price to Earnings Ratio|Business Payback Period Cyclerion Therapeutics CYCN|protagenic.com (PTIX) - Price to Earnings Ratio|Price to Earnings Multiple KTTA|CRGT (Cortigent Inc) - P/E Multiple|Market Cap to Earnings avenuetx.com ATXI|Price to Earnings Ratio BCLI (BrainStorm Cell Therapeutics)|P/E Multiple Cara Therapeutics Inc. (CARA)|Price to Earnings Ratio Chromocell Therapeutics Corporation CHRO|Company Value to Net Income ELYM|ITCI - Price to Earnings Ratio|Market Cap to Earnings longboardpharma.com|Marinus Pharmaceuticals, Inc. (MRNS) - Price to Earnings Ratio|NKGN: Market Price to Net Income Ratio|Price to Earnings Ratio NRBO|P/E Multiple Sage Therapeutics Inc|Price to Earnings Ratio Synaptogenix, Inc. (SNPX)|TRVN: Market Cap to Net Income|P/E Multiple VIGL (Vigil Neuroscience, Inc.)|Business Payback Period anewmeds.com (WENA)|CERE: Price to Earnings Ratio
